OKYO OKYO Pharma (OKYO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001849296
Cluster · 6 insidersC-suite buying · 4
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter
What the filings say about OKYO
Insiders, 180 days
+$136.0K net bought
6 buyers
OKYO Pharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, OKYO Pharma Ltd insiders bought a net $136.0K of stock across 13 Form 4 purchases and sales, with 6 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 16.8% of the 20,030 shares held after it.
- 5 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Patil Rajkumar V. bought about $5.0K of OKYO on Jul 27, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 15,000 shares held after it.
- 5 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Dempsey Robert John bought about $23.1K of OKYO on Jul 22, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 15, 2023.
- The trade is 14.2% of the 35,201 shares held after it.
- 5 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BRANCACCIO JOHN P bought about $7.4K of OKYO on Jul 21, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 19, 2022.
- The trade is 3.1% of the 112,420 shares held after it.
- 5 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF DEVELOPMENT OFFICER JACOB GARY S bought about $4.9K of OKYO on Jul 21, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jul 20, 2026.
- -32.1% median (-23.8% mean) 90-day return after 3 previous buys.
- The trade is 0.2% of the 10,873,916 shares held after it.
- 5 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CERRONE GABRIELE M bought about $32.6K of OKYO on Jul 21, 2026; 5 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$136.0K over 180 days
+$67.6K of it by a 10%+ holder
more than 77% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 82% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.3% of the float short (float per yahoo 2026-10-27) · 1.8 days to cover · settled 2026-10-15
below 87% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 7 in the prior 90
Why it matters
The absence is the signal: 7 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch OKYO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-35.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns OKYO: institutional holders (13F)
13F holdings, latest reported quarter
3,652,768 sh
$5.5M
1,725,992 sh
$2.6M
809,317 sh
$1.2M
580,596 sh
$870.9K
375,204 sh
$562.8K
Congress trades in OKYO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
OKYO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
3 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
0 active
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
6 insiders reported buying shares.
The record shows a net $136.0K bought by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
OKYO financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-03 | 2024-03 | 2023-03 | 2022-03 | |
|---|---|---|---|---|
| Net income | -$4.7M | -$16.8M | -$13.3M | -$5.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
OKYO Stock Sonar score 3/7 axes
Find similar shapesCompareOKYO ranks highest on risk and compliance (89th percentile) and insider conviction (87th), and lowest on institutional and government (18th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OKYO filings, in plain words
Are OKYO Pharma insiders buying or selling OKYO?
In the 180 days to 2026-10-28, OKYO Pharma insiders were net buyers, a net $136.0K across purchases and sales reported on Form 4, by 6 buyers.
Read the full summary
In the 180 days to 2026-10-28, OKYO Pharma insiders were net buyers of OKYO, a net $136.0K across purchases and sales reported on Form 4 by 6 buyers. 6 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
